Anzeige
Meldung des Tages: Warum diese Aktie einer der großen Gewinner im neuen Goldzyklus sein könnte

Q32 Bio Aktie News

Aktie
WKN:  A4ZZ0Z ISIN:  US7469641051 US-Symbol:  QTTB Branche:  Biotechnologie Land:  USA
3,52 €
-0,02 €
-0,56%
10:43:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
33,16 Mio. €
Streubesitz
29,10%
KGV
-0,88
Index-Zuordnung
-

Q32 Bio News

01.12.25 - PR Newswire
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire
13.11.25 - PR Newswire
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
21.10.25 - PR Newswire
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata PR Newswire
28.08.25 - PR Newswire
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference PR Newswire
06.08.25 - PR Newswire
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
25.06.25 - PR Newswire
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer PR Newswire
08.05.25 - PR Newswire
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
30.04.25 - PR Newswire
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata PR Newswire
16.04.25 - PR Newswire
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
Q32 Bio Doses First Patients in Both Part A Open-​Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata PR Newswire
11.03.25 - PR Newswire
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
08.03.25 - PR Newswire
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting PR ...
28.02.25 - PR Newswire
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
Q32 Bio Announces Late-​Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology ...
26.02.25 - PR Newswire
Q32 Bio to Participate in Upcoming March Investor Conferences
Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire
10.02.25 - PR Newswire
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata PR Newswire
04.02.25 - PR Newswire
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »